High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis

Antzeko izenburuak

• Further comments on “High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis”
  nork: Messori, Andrea, et al.
  Argitaratua: (2019)
• Reply to “High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis” by Messori et al.
  nork: Farrugia, Albert, et al.
  Argitaratua: (2019)
• Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better
  nork: Mannucci, Pier Mannuccio
  Argitaratua: (2010)
• Factor VIII inhibitor and source of replacement therapy
  nork: Mannucci, Pier Mannuccio, et al.
  Argitaratua: (2012)
• Factor VIII replacement is still the standard of care in haemophilia A
  nork: Aledort, Louis, et al.
  Argitaratua: (2019)